Research Article 
Diabetic retinopathy screening: a systematic review of the economic evidence
Diabetic Medicine, 2010, 27(3), 249-256. DOI: 10.1111/j.1464-5491.2009.02870.x
Abstract
This paper systematically reviews the published literature on the economic evidence of diabetic retinopathy screening. Twenty-nine electronic databases were searched for studies published between 1998 and 2008. Internet searches were carried out and reference lists of key studies were hand searched for relevant articles. The key search terms used were ‘diabetic retinopathy’, ‘screening’, ‘economic’ and ‘cost’. The search identified 416 papers of which 21 fulfilled the inclusion criteria, comprising nine cost-effectiveness studies, one cost analysis, one cost-minimization analysis, four cost-utility analyses and six reviews. Eleven of the included studies used economic modelling techniques and/or computer simulation to assess screening strategies. To date, the economic evaluation literature on diabetic retinopathy screening has focused on four key questions: the overall cost-effectiveness of ophthalmic care; the cost-effectiveness of systematic vs. opportunistic screening; how screening should be organized and delivered; and how often people should be screened. Systematic screening for diabetic retinopathy is cost-effective in terms of sight years preserved compared with no screening. Digital photography with telemedicine links has the potential to deliver cost-effective, accessible screening to rural, remote and hard-to-reach populations. Variation in compliance rates, age of onset of diabetes, glycaemic control and screening sensitivities influence the cost-effectiveness of screening programmes and are important sources of uncertainty in relation to the issue of optimal screening intervals. There is controversy in relation to the economic evidence on optimal screening intervals. Further research is needed to address the issue of optimal screening interval, the opportunities for targeted screening to reflect relative risk and the effect of different screening intervals on attendance or compliance by patients.
ASCI-ID: 109-686
Similar Articles
Motivational enhancement therapy with and without cognitive behaviour therapy for Type 1 diabetes: economic evaluation from a randomized controlled trial
Diabetic Medicine, 2011, 28(4), 470-479. DOI: 10.1111/j.1464-5491.2010.03198.x
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitusDiabetic Medicine, 2012, 29(3), 313-320. DOI: 10.1111/j.1464-5491.2011.03429.x
The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy ModelDiabetic Medicine, 2013, 30(10), 1236-1244. DOI: 10.1111/dme.12270
Assessing the cost-effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy ModelDiabetic Medicine, 2014, 31(4), 477-486. DOI: 10.1111/dme.12371
Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysisDiabetic Medicine, 2014, 31(5), 615-623. DOI: 10.1111/dme.12366
Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population—the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4Diabetic Medicine, 2008, 25(5), 536-542. DOI: 10.1111/j.1464-5491.2008.02423.x
Health utility values associated with diabetic retinopathyDiabetic Medicine, 2008, 25(5), 618-624. DOI: 10.1111/j.1464-5491.2008.02430.x
The Y402H variant of complement factor H is associated with age-related macular degeneration but not with diabetic retinal disease in the Go-DARTS studyDiabetic Medicine, 2009, 26(5), 460-465. DOI: 10.1111/j.1464-5491.2009.02719.x
Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age populationDiabetic Medicine, 2009, 26(5), 489-492. DOI: 10.1111/j.1464-5491.2009.02718.x
Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programmeDiabetic Medicine, 2009, 26(10), 1040-1047. DOI: 10.1111/j.1464-5491.2009.02820.x
Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetesDiabetic Medicine, 2010, 27(4), 431-435.
Is risk of diabetic retinopathy lower in Australia’s Greek-born migrants?Diabetic Medicine, 2010, 27(6), 660-665. DOI: 10.1111/j.1464-5491.2010.03005.x
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT ProgrammeDiabetic Medicine, 2011, 28(3), 345-351. DOI: 10.1111/j.1464-5491.2010.03210.x
Increased levels of monokine induced by interferon-γ (Mig) in the vitreous of patients with diabetic retinopathyDiabetic Medicine, 2008, 25(7), 875-877. DOI: 10.1111/j.1464-5491.2008.02466.x
Reliability of screening methods for diabetic retinopathyDiabetic Medicine, 2009, 26(8), 783-790. DOI: 10.1111/j.1464-5491.2009.02778.x
Blood pressure control and awareness among patients with diabetes and hypertension attending a tertiary ophthalmic clinicDiabetic Medicine, 2009, 26(1), 34-39. DOI: 10.1111/j.1464-5491.2008.02614.x
Socio-economic and ethnic inequalities in diabetes retinal screeningDiabetic Medicine, 2010, 27(3), 282-288. DOI: 10.1111/j.1464-5491.2010.02946.x
Association between alcohol consumption and diabetic retinopathy and visual acuity-the AdRem StudyDiabetic Medicine, 2010, 27(10), 1130-1137. DOI: 10.1111/j.1464-5491.2010.03080.x
Agreement and reasons for disagreement between photographic and hospital biomicroscopy grading of diabetic retinopathyDiabetic Medicine, 2011, 28(6), 741-746. DOI: 10.1111/j.1464-5491.2011.03273.x
Do type 2 diabetes patients without diabetic retinopathy or subjects with impaired fasting glucose have impaired colour vision? The Okubo Color Study ReportDiabetic Medicine, 2011, 28(7), 865-871. DOI: 10.1111/j.1464-5491.2011.03290.x
External quality assurance for image grading in the Scottish Diabetic Retinopathy Screening ProgrammeDiabetic Medicine, 2012, 29(6), 776-783. DOI: 10.1111/j.1464-5491.2011.03504.x
Preferences of people with diabetes for diabetic retinopathy screening: a discrete choice experimentDiabetic Medicine, 2012, 29(7), 869-877. DOI: 10.1111/j.1464-5491.2012.03636.x
Diabetic retinopathy screening: perspectives of people with diabetes, screening intervals and costs of attending screeningDiabetic Medicine, 2012, 29(7), 878-885. DOI: 10.1111/j.1464-5491.2012.03637.x
Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countriesDiabetic Medicine, 2013, 30(4), 387-398. DOI: 10.1111/dme.12119
Should diabetes retinal screening intervals change?Diabetic Medicine, 2013, 30(1), 43-45. DOI: 10.1111/j.1464-5491.2012.03752.x
Patient safety systems in the primary health care of diabetes-a story of missed opportunities?Diabetic Medicine, 2010, 27(11), 1322-1326. DOI: 10.1111/j.1464-5491.2010.03106.x
Association between childhood obesity and subsequent Type 1 diabetes: a systematic review and meta-analysisDiabetic Medicine, 2011, 28(1), 10-18. DOI: 10.1111/j.1464-5491.2010.03160.x
Nurse-led interventions used to improve control of high blood pressure in people with diabetes: a systematic review and meta-analysisDiabetic Medicine, 2011, 28(3), 250-261. DOI: 10.1111/j.1464-5491.2010.03204.x
Unresolved issues in the management of ulcers of the foot in diabetesDiabetic Medicine, 2008, 25(12), 1380-1389. DOI: 10.1111/j.1464-5491.2008.02573.x
Exenatide efficacy and safety: a systematic reviewDiabetic Medicine, 2009, 26(9), 837-846. DOI: 10.1111/j.1464-5491.2009.02790.x
Alterations of tendons in patients with diabetes mellitus: a systematic reviewDiabetic Medicine, 2011, 28(8), 886-895. DOI: 10.1111/j.1464-5491.2010.03197.x
Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic reviewDiabetic Medicine, 2013, 30(11), 1272-1292. DOI: 10.1111/dme.12274
The use of technology to promote physical activity in Type 2 diabetes management: a systematic reviewDiabetic Medicine, 2013, 30(12), 1420-1432. DOI: 10.1111/dme.12289